De novo SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from Nicolaides-Baraitser syndrome.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
11 2020
Historique:
received: 23 03 2020
accepted: 26 06 2020
revised: 25 06 2020
pubmed: 23 7 2020
medline: 29 4 2021
entrez: 23 7 2020
Statut: ppublish

Résumé

Nontruncating variants in SMARCA2, encoding a catalytic subunit of SWI/SNF chromatin remodeling complex, cause Nicolaides-Baraitser syndrome (NCBRS), a condition with intellectual disability and multiple congenital anomalies. Other disorders due to SMARCA2 are unknown. By next-generation sequencing, we identified candidate variants in SMARCA2 in 20 individuals from 18 families with a syndromic neurodevelopmental disorder not consistent with NCBRS. To stratify variant interpretation, we functionally analyzed SMARCA2 variants in yeasts and performed transcriptomic and genome methylation analyses on blood leukocytes. Of 20 individuals, 14 showed a recognizable phenotype with recurrent features including epicanthal folds, blepharophimosis, and downturned nasal tip along with variable degree of intellectual disability (or blepharophimosis intellectual disability syndrome [BIS]). In contrast to most NCBRS variants, all SMARCA2 variants associated with BIS are localized outside the helicase domains. Yeast phenotype assays differentiated NCBRS from non-NCBRS SMARCA2 variants. Transcriptomic and DNA methylation signatures differentiated NCBRS from BIS and those with nonspecific phenotype. In the remaining six individuals with nonspecific dysmorphic features, clinical and molecular data did not permit variant reclassification. We identified a novel recognizable syndrome named BIS associated with clustered de novo SMARCA2 variants outside the helicase domains, phenotypically and molecularly distinct from NCBRS.

Identifiants

pubmed: 32694869
doi: 10.1038/s41436-020-0898-y
pii: S1098-3600(21)00785-1
doi:

Substances chimiques

SMARCA2 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1838-1850

Subventions

Organisme : Wellcome Trust
ID : 209568/Z/17/Z
Pays : United Kingdom
Organisme : Telethon
ID : GSP15001
Pays : Italy
Organisme : Department of Health
Pays : United Kingdom

Investigateurs

Vincenzo Nigro (V)
Nicola Brunetti-Pierri (N)
Giorgio Casari (G)
Gerarda Cappuccio (G)
Annalaura Torella (A)
Michele Pinelli (M)
Francesco Musacchia (F)
Margherita Mutarelli (M)
Diego Carrella (D)
Giuseppina Vitiello (G)
Valeria Capra (V)
Giancarlo Parenti (G)
Vincenzo Leuzzi (V)
Angelo Selicorni (A)
Silvia Maitz (S)
Sandro Banfi (S)
Marcella Zollino (M)
Mario Montomoli (M)
Donatelli Milani (D)
Corrado Romano (C)
Albina Tummolo (A)
Daniele De Brasi (D)
Antonietta Coppola (A)
Claudia Santoro (C)
Angela Peron (A)
Chiara Pantaleoni (C)
Raffaele Castello (R)
Stefano D'Arrigo (S)

Références

Menke LA, study DDD, Gardeitchik T, et al. Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome. Am J Med Genet A. 2018;176:862–876.
Hansen AW, Murugan M, Li H, et al. A genocentric approach to discovery of Mendelian disorders. Am J Hum Genet. 2019;105:974–986.
pubmed: 31668702 pmcid: 31668702
Karaca E, Posey JE, Coban Akdemir Z, et al. Phenotypic expansion illuminates multilocus pathogenic variation. Genet Med. 2018;20:1528–1537.
pubmed: 29790871 pmcid: 6450542
Schulze TG, McMahon FJ. Defining the phenotype in human genetic studies: forward genetics and reverse phenotyping. Hum Hered. 2004;58:131–138.
Hennekam RC, Biesecker LG. Next-generation sequencing demands next-generation phenotyping. Hum Mutat. 2012;33:884–886.
pubmed: 22457028 pmcid: 3327792
Nicolaides P, Baraitser M. An unusual syndrome with mental retardation and sparse hair. Clin Dysmorphol. 1993;2:232–236.
Sousa SB, Hennekam RC, Nicolaides-Baraitser Syndrome International Consortium. Phenotype and genotype in Nicolaides–Baraitser syndrome. Am J Med Genet C Semin Med Genet. 2014;166C:302–314.
Van Houdt JK, Nowakowska BA, Sousa SB, et al. Heterozygous missense mutations in SMARCA2 cause Nicolaides–Baraitser syndrome. Nat Genet. 2012;44:445–9, S441.
Wolff D, Endele S, Azzarello-Burri S, et al. In-frame deletion and missense mutations of the C-Terminal Helicase Domain of SMARCA2 in three patients with Nicolaides–Baraitser syndrome. Mol Syndromol. 2012;2:237–244.
pubmed: 22822383 pmcid: 3362220
Borlot F, Regan BM, Bassett AS, Stavropoulos DJ, Andrade DM. Prevalence of pathogenic copy number variation in adults with pediatric-onset epilepsy and intellectual disability. JAMA Neurol. 2017;74:1301–1311.
pubmed: 28846756 pmcid: 28846756
Sekiguchi F, Tsurusaki Y, Okamoto N, et al. Genetic abnormalities in a large cohort of Coffin–Siris syndrome patients. J Hum Genet. 2019;64:1173–1186.
pubmed: 31530938 pmcid: 31530938
Santen GW, Kriek M, van Attikum H. SWI/SNF complex in disorder: switching from malignancies to intellectual disability. Epigenetics. 2012;7:1219–1224.
pubmed: 23010866 pmcid: 23010866
Bramswig NC, Ludecke HJ, Alanay Y, et al. Exome sequencing unravels unexpected differential diagnoses in individuals with the tentative diagnosis of Coffin–Siris and Nicolaides–Baraitser syndromes. Hum Genet. 2015;134:553–568.
pubmed: 25724810 pmcid: 25724810
Ejaz R, Babul-Hirji R, Chitayat D. The evolving features of Nicolaides–Baraitser syndrome—a clinical report of a 20-year follow-up. Clin Case Rep. 2016;4:351–355.
pubmed: 27099726 pmcid: 27099726
Tang S, Hughes E, Lascelles K, Euro ERESmaewg, Simpson MA, Pal DK. New SMARCA2 mutation in a patient with Nicolaides–Baraitser syndrome and myoclonic astatic epilepsy. Am J Med Genet A. 2017;173:195–199.
pubmed: 27665729 pmcid: 27665729
Gripp KW, Baker L, Telegrafi A, Monaghan KG. The role of objective facial analysis using FDNA in making diagnoses following whole exome analysis. Report of two patients with mutations in the BAF complex genes. Am J Med Genet A. 2016;170:1754–1762.
pubmed: 27112773 pmcid: 27112773
Wieczorek D, Bogershausen N, Beleggia F, et al. A comprehensive molecular study on Coffin–Siris and Nicolaides–Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. Hum Mol Genet. 2013;22:5121–5135.
pubmed: 23906836 pmcid: 23906836
Sanchez AI, Rojas JA. A SMARCA2 mutation in the first case report of Nicolaides–Baraitser syndrome in Latin America: genotype-phenotype correlation. Case Rep Genet. 2017;2017:8639617.
pubmed: 28948053 pmcid: 28948053
Tsurusaki Y, Okamoto N, Ohashi H, et al. Mutations affecting components of the SWI/SNF complex cause Coffin–Siris syndrome. Nat Genet. 2012;44:376–378.
pubmed: 22426308 pmcid: 22426308
Santen GW, Aten E, Vulto-van Silfhout AT, et al. Coffin–Siris syndrome and the BAF complex: genotype–phenotype study in 63 patients. Hum Mutat. 2013;34:1519–1528.
Yamamoto T, Imaizumi T, Yamamoto-Shimojima K, et al. Genomic backgrounds of Japanese patients with undiagnosed neurodevelopmental disorders. Brain Dev. 2019;41:776–782.
Mari F, Marozza A, Mencarelli MA, et al. Coffin–Siris and Nicolaides–Baraitser syndromes are a common well recognizable cause of intellectual disability. Brain Dev. 2015;37:527–536.
Kosho T, Okamoto N, Ohashi H, et al. Clinical correlations of mutations affecting six components of the SWI/SNF complex: detailed description of 21 patients and a review of the literature. Am J Med Genet A. 2013;161A:1221–1237.
Aref-Eshghi E, Bend EG, Hood RL, et al. BAFopathies’ DNA methylation epi-signatures demonstrate diagnostic utility and functional continuum of Coffin–Siris and Nicolaides–Baraitser syndromes. Nat Commun. 2018;9:4885.
pubmed: 30459321 pmcid: 6244416
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–930.
pubmed: 26220891 pmcid: 4833888
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
pubmed: 25741868 pmcid: 25741868
Shaw WM, Yamauchi H, Mead J, et al. Engineering a model cell for rational tuning of GPCR signaling. Cell. 2019;177:782–96. e727.
pubmed: 30955892 pmcid: 6476273
Gurovich Y, Hanani Y, Bar O, et al. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med. 2019;25:60–64.
Li M, Xia X, Tian Y, et al. Mechanism of DNA translocation underlying chromatin remodelling by Snf2. Nature. 2019;567:409–413.
pubmed: 30867599 pmcid: 30867599
Mashtalir N, D’Avino AR, Michel BC, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell. 2018;175:1272–88. e1220.
pubmed: 30343899 pmcid: 30343899
Schubert HL, Wittmeyer J, Kasten MM, et al. Structure of an actin-related subcomplex of the SWI/SNF chromatin remodeler. Proc Natl Acad Sci U S A. 2013;110:3345–3350.
pubmed: 23401505 pmcid: 23401505
Han Y, Reyes AA, Malik S, He Y. Cryo-EM structure of SWI/SNF complex bound to a nucleosome. Nature. 2020;579:452–455.
pubmed: 32188938 pmcid: 32188938
Neigeborn L, Carlson M. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics. 1984;108:845–858.
pubmed: 1224269 pmcid: 1224269
Minard LV, Lin LJ, Schultz MC. SWI/SNF and Asf1 independently promote derepression of the DNA damage response genes under conditions of replication stress. PLoS ONE. 2011;6:e21633.
pubmed: 21738741 pmcid: 21738741
Chater-Diehl E, Ejaz R, Cytrynbaum C, et al. New insights into DNA methylation signatures: SMARCA2 variants in Nicolaides–Baraitser syndrome. BMC Med Genomics. 2019;12:105.
pubmed: 31288860 pmcid: 31288860
van der Sluijs PJ, Jansen S, Vergano SA, et al. The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin–Siris syndrome. Genet Med. 2019;21:1295–1307.
pubmed: 30349098 pmcid: 30349098
Krawitz P, Buske O, Zhu N, Brudno M, Robinson PN. The genomic birthday paradox: how much is enough? Hum Mutat. 2015;36:989–997.
pubmed: 26239817 pmcid: 26239817
Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci. 2014;17:764–772.
pubmed: 24866042 pmcid: 24866042
Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312:1880–1887.
pubmed: 25326637 pmcid: 25326637
Vandeweyer G, Helsmoortel C, Van Dijck A, et al. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014;166C:315–326.
Takenouchi T, Miwa T, Sakamoto Y, et al. Further evidence that a blepharophimosis syndrome phenotype is associated with a specific class of mutation in the ADNP gene. Am J Med Genet A. 2017;173:1631–1634.
Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem. 2007;282:34448–34456.

Auteurs

Gerarda Cappuccio (G)

Department of Translational Medicine, Federico II University, Naples, Italy.
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.

Camille Sayou (C)

Inserm U1209, CNRS UMR 5309, Univ. Grenoble Alpes, Institute for Advanced Biosciences, Grenoble, France.

Pauline Le Tanno (PL)

Department of Genetics and Reproduction, Centre Hospitalo-Universitaire Grenoble-Alpes, Grenoble, France.

Emilie Tisserant (E)

Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.

Ange-Line Bruel (AL)

Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.

Sara El Kennani (SE)

Inserm U1209, CNRS UMR 5309, Univ. Grenoble Alpes, Institute for Advanced Biosciences, Grenoble, France.

Joaquim Sá (J)

Medical Genetics Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.

Karen J Low (KJ)

University Hospitals Bristol NHS Foundation Trust, University of Bristol, Bristol, UK.

Cristina Dias (C)

Department of Medical and Molecular Genetics, King's College, London, UK.
The Francis Crick Institute, London, UK.
Clinical Genetics, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Markéta Havlovicová (M)

Department of Biology and Medical Genetics, Charles University Prague 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Miroslava Hančárová (M)

Department of Biology and Medical Genetics, Charles University Prague 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

Evan E Eichler (EE)

Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.

Françoise Devillard (F)

Department of Genetics and Reproduction, Centre Hospitalo-Universitaire Grenoble-Alpes, Grenoble, France.

Sébastien Moutton (S)

CPDPN, Pôle mère enfant, Maison de Santé Protestante Bordeaux Bagatelle, Talence, France.

Julien Van-Gils (J)

Reference Center for Developmental Anomalies, Department of Medical Genetics, Bordeaux University Hospital, Bordeaux, France.

Christèle Dubourg (C)

Service de Génétique Moléculaire et Génomique, BMT-HC « Jean Dausset », Rennes, France.

Sylvie Odent (S)

Service de Génétique clinique, CHU de Rennes, Univ. Rennes, Institut de Génétique et Développement de Rennes (IGDR) UMR 6290, Rennes, France.

Bénédicte Gerard (B)

Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Amélie Piton (A)

Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Toshiyuki Yamamoto (T)

Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.
Tokyo Women's Medical University Institute of Integrated Medical Sciences, Tokyo, Japan.

Nobuhiko Okamoto (N)

Department of Medical Genetics, Osaka Women's and Children's Hospital, Osaka, Japan.

Helen Firth (H)

Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.

Kay Metcalfe (K)

Manchester Centre for Genomic Medicine, Manchester, UK.

Anna Moh (A)

Department of Genetics and Metabolism, Children's National Medical Center, Washington, DC, USA.

Kimberly A Chapman (KA)

Department of Genetics and Metabolism, Children's National Medical Center, Washington, DC, USA.

Erfan Aref-Eshghi (E)

Molecular Genetics Laboratory, Victoria Hospital, London Health Sciences Centre, London, ON, Canada.
Department of Pathology and Laboratory Medicine, Western University, London, Canada.

Jennifer Kerkhof (J)

Molecular Genetics Laboratory, Victoria Hospital, London Health Sciences Centre, London, ON, Canada.

Annalaura Torella (A)

Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Vincenzo Nigro (V)

Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Laurence Perrin (L)

Department of Genetics, Robert Debré Hospital, AP-HP, Paris, France.

Juliette Piard (J)

Centre de génétique humaine, Université de Franche-Comté, Besançon, France.

Gwenaël Le Guyader (G)

Department of Medical Genetics, Poitiers University Hospital, Poitiers, France.

Thibaud Jouan (T)

Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.

Christel Thauvin-Robinet (C)

Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.
Centre de Référence Déficiences Intellectuelles de Causes Rares, CHU Dijon, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon, Dijon, France.

Yannis Duffourd (Y)

Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.

Jaya K George-Abraham (JK)

Dell Children's Medical Group, Austin, TX, USA.
Department of Pediatrics, The University of Texas at Austin Dell Medical School, Austin, TX, USA.

Catherine A Buchanan (CA)

Dell Children's Medical Group, Austin, TX, USA.

Denise Williams (D)

Birmingham Women's NHS Foundation Trust, Birmingham, UK.

Usha Kini (U)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Kate Wilson (K)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Sérgio B Sousa (SB)

Medical Genetics Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
University Clinic of Genetics, Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal.

Raoul C M Hennekam (RCM)

Department of Pediatrics and Translational Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Bekim Sadikovic (B)

Molecular Genetics Laboratory, Victoria Hospital, London Health Sciences Centre, London, ON, Canada.
Department of Pathology and Laboratory Medicine, Western University, London, Canada.

Julien Thevenon (J)

Department of Genetics and Reproduction, Centre Hospitalo-Universitaire Grenoble-Alpes, Grenoble, France.

Jérôme Govin (J)

Inserm U1209, CNRS UMR 5309, Univ. Grenoble Alpes, Institute for Advanced Biosciences, Grenoble, France. Jerome.Govin@univ-grenoble-alpes.fr.

Antonio Vitobello (A)

Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France. Antonio.Vitobello@u-bourgogne.fr.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon, Dijon, France. Antonio.Vitobello@u-bourgogne.fr.

Nicola Brunetti-Pierri (N)

Department of Translational Medicine, Federico II University, Naples, Italy. brunetti@tigem.it.
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy. brunetti@tigem.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH